Comparison of IL-2- and IL-4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine

Gene Therapy

Volumn 3, Issue 10, 1996, Pages 853-858

  Souberbielle, B E ^a   Knight, B C ^a   Morrow, Wjw ^b   Darling, D ^c   Fraziano, M ^a   Marriott, J B ^a   Cookson, S ^a   Farzaneh, F ^c   Dalgleish, A G ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adjuvant; B16 F10; Cytokine; Melanoma; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; INTERLEUKIN 4; OIL; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER MODEL; COMPARATIVE STUDY; CONTROLLED STUDY; DNA TRANSFECTION; EMULSION; FEMALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALUM COMPOUNDS; ANIMALS; CANCER VACCINES; CELL LINE; FEMALE; FREUND'S ADJUVANT; INTERLEUKIN-2; INTERLEUKIN-4; MELANOMA; MICE; MICE, INBRED C57BL; OILS; TRANSFECTION; TUMOR CELLS, CULTURED; VACCINATION; VACCINES, DNA;

ANIMALIA; MURINAE;

EID: 0029860734     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Jaffe EM, Hurwitz H, Pardoll DM. Gene modification of tumors. In. VT DeVita, S Hellman, SA Rosenberg (eds). Biological Therapy of Cancer, 2nd edn. JB Lippincott Company. Philadelphia, 1995, pp 774-783.
2. Dalgleish AG. Cancer vaccines. Eur J Cancer 1994; 30A: 1029-1035.
3. Morton DL et al. Prolongation of survival in metastatic melanoma after specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463-482.
4. Earth A et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994; 54: 3342-3345.
5. Gupta RK, Siber GR. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995; 13: 1263-1276.
6. - cytotoxic T cell responses? A paradox revisited, Immunol Today 1993; 14: 344-348.
7. Raychaudhuri S et al. Induction of antigen-specific class-I restricted cytotoxic cells by soluble proteins in vivo. Proc Natl Acad Sci USA 1992; 89: 8308-8312.
8. Hunter RL, Strickland F, Kezdy F. The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophilelipophile balance. J Immunol 1981; 127: 1244-1250.
9. Hariharan K et al. The induction of cytotoxic T cells and tumour regression by soluble antigen formulation. Cancer Res 1995; 55: 3486-3489.
10. Hanna MG Jr, Peters IC. Immunotherapy of established micrometastases with bacillus Calmette-Guerin tumour cell vaccine. Cancer Res 1978; 38: 204-209.
11. Chen L et al. Tumour immunogenicity determines the effect of B7 costimulation on T cell mediated tumour immunity. J Exp Med 1994; 179: 523-532.
12. Huang AY et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-965.
13. Maass G et al. Priming of tumor-specific T cells in the draining lymph nodes after immunization with IL-2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 1995; 92: 5540-5544.
14. Hock H et al. Vaccination with tumor cells genetically engmeered to produce different cytokines effectively not superior to a classical adjuvant. Cancer Res 1993; 53: 714-716.
15. Allione A et al. Immunizing and curative potential of nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (ID)-2, IL-4, IL-6, IL-7, IL-10, tumour necrosis factor alpha, granulocyte-macrophage colony-stimulating factor and gamma interferon gene or admixed with conventional adjuvant. Cancer Res 1995; 54: 6022-6026.
16. Chen L et al. B7-1 /CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacternum parvum Cancer Res 1994; 54: 5420-5423.
17. Schmidt W et al. Cancer vaccines: the interleukin-2 dosage effect. Proc Natl Acad Sci USA 1995; 92: 4711-4714.
18. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543
19. Qin HX, Chatterjee SK. Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumour vaccine. Gene Therapy 1996; 3: 59-66.
20. Fidler IJ, Kripke ML. Metastasis results from pre-existing variants cells within a malignant tumor. Science 1977; 197: 893-895.
21. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400-406.